Clarisse Kerleau1, Anne-Valérie Guizard2, Laetitia Daubisse-Marliac3, Natacha Heutte4, Mariette Mercier5, Pascale Grosclaude6, Florence Joly7. 1. Calvados General Tumor Registry, François Baclesse Cancer Center, Caen, France. Electronic address: clarisse.kerleau@orange.fr. 2. Calvados General Tumor Registry, François Baclesse Cancer Center, Caen, France; UMR 1086 « Cancers et Préventions », Inserm - University of Basse-Normandie, Caen, France. 3. Tarn Cancer Registry, Albi, France; Claudius Regaud Institute, IUCT-O, Tarn Cancer Registry, Toulouse, France. 4. UMR 1086 « Cancers et Préventions », Inserm - University of Basse-Normandie, Caen, France; Quality of Life in Oncology National Platform, France. 5. EA 3181, SFR-FED 4234, University of Franche Comté, France. 6. Claudius Regaud Institute, IUCT-O, Tarn Cancer Registry, Toulouse, France. 7. UMR 1086 « Cancers et Préventions », Inserm - University of Basse-Normandie, Caen, France; Department of Medical Oncology, François Baclesse Cancer Center, Caen, France; CHU Côte de Nacre, University of Basse-Normandie, Caen, France.
Abstract
BACKGROUND: To evaluate quality of life (QoL) 10 years after treatments for localised prostate cancer (LPCa) patients in comparison with aged-matched healthy controls. METHODS: LPCa patients diagnosed in 2001 were obtained from 11 French cancer registries. Controls were recruited among the general population and were matched to patients on age and geographic area. EORTC Quality of Life Questionnaire - Core 30 items, Expanded Prostate Cancer Index Composite, Hospital Anxiety and Depression Scale and Multidimensional Fatigue Inventory self-reported questionnaires were used to measure QoL, anxiety and fatigue. Patients were classified in three groups according to previous treatments: radical prostatectomy (RP), radiotherapy (RT) and radical prostatectomy and radiotherapy (RP+RT). The differences in QoL between patients and controls and according to treatment groups were evaluated. RESULTS: There were 287 patients and 287 controls. There was no socio-demographic difference between patients and controls. Treatments were: RP (143), RT (78), PR+RT (33), baseline hormone therapy (49) and hormone therapy at the time of the study (34). Patients had similar levels of global QoL, anxiety, depression and fatigue as controls. They reported more urinary troubles (urinary function and incontinence) (p < 0.0001) and more sexual dysfunctions (p < 0.0001) than controls, whatever the treatment group. Worse bowel dysfunction was reported in patients treated by RT and RP+RT (p < 0.002). According to the treatments, RP groups had the worst urinary function and incontinence (p < 0.01), and reported more bowel bother when the treatment was combined with RT. CONCLUSIONS: Even though patients reported similar global QoL as control 10 years after treatment, patients reported numerous urinary and sexual dysfunctions. Patients treated with RP+RT reported cumulative sequelae of both treatments.
BACKGROUND: To evaluate quality of life (QoL) 10 years after treatments for localised prostate cancer (LPCa) patients in comparison with aged-matched healthy controls. METHODS: LPCa patients diagnosed in 2001 were obtained from 11 French cancer registries. Controls were recruited among the general population and were matched to patients on age and geographic area. EORTC Quality of Life Questionnaire - Core 30 items, Expanded Prostate Cancer Index Composite, Hospital Anxiety and Depression Scale and Multidimensional Fatigue Inventory self-reported questionnaires were used to measure QoL, anxiety and fatigue. Patients were classified in three groups according to previous treatments: radical prostatectomy (RP), radiotherapy (RT) and radical prostatectomy and radiotherapy (RP+RT). The differences in QoL between patients and controls and according to treatment groups were evaluated. RESULTS: There were 287 patients and 287 controls. There was no socio-demographic difference between patients and controls. Treatments were: RP (143), RT (78), PR+RT (33), baseline hormone therapy (49) and hormone therapy at the time of the study (34). Patients had similar levels of global QoL, anxiety, depression and fatigue as controls. They reported more urinary troubles (urinary function and incontinence) (p < 0.0001) and more sexual dysfunctions (p < 0.0001) than controls, whatever the treatment group. Worse bowel dysfunction was reported in patients treated by RT and RP+RT (p < 0.002). According to the treatments, RP groups had the worst urinary function and incontinence (p < 0.01), and reported more bowel bother when the treatment was combined with RT. CONCLUSIONS: Even though patients reported similar global QoL as control 10 years after treatment, patients reported numerous urinary and sexual dysfunctions. Patients treated with RP+RT reported cumulative sequelae of both treatments.
Authors: Salome Adam; Daniela Doege; Lena Koch-Gallenkamp; Melissa S Y Thong; Heike Bertram; Andrea Eberle; Bernd Holleczek; Ron Pritzkuleit; Mechthild Waldeyer-Sauerland; Annika Waldmann; Sylke Ruth Zeissig; Lina Jansen; Sabine Rohrmann; Hermann Brenner; Volker Arndt Journal: Support Care Cancer Date: 2019-11-18 Impact factor: 3.603
Authors: Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal Journal: Health Technol Assess Date: 2020-08 Impact factor: 4.014
Authors: Ted A Skolarus; Tabitha Metreger; Soohyun Hwang; Hyungjin Myra Kim; Robert L Grubb; Jeffrey R Gingrich; Sarah T Hawley Journal: Trials Date: 2017-04-18 Impact factor: 2.279
Authors: Agnieszka Lemanska; Karen Poole; Bruce A Griffin; Ralph Manders; John M Saxton; Lauren Turner; Joe Wainwright; Sara Faithfull Journal: BMJ Open Date: 2019-06-11 Impact factor: 2.692